These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 36113895)

  • 1. Intratumoral administration of CD1c (BDCA-1)
    Schwarze JK; Tijtgat J; Awada G; Cras L; Vasaturo A; Bagnall C; Forsyth R; Dufait I; Tuyaerts S; Van Riet I; Neyns B
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36113895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral Combinatorial Administration of CD1c (BDCA-1)
    Schwarze JK; Awada G; Cras L; Tijtgat J; Forsyth R; Dufait I; Tuyaerts S; Van Riet I; Neyns B
    Vaccines (Basel); 2020 Nov; 8(4):. PubMed ID: 33182610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral administration of the immunologic adjuvant AS01
    Tijtgat J; Geeraerts X; Boisson A; Stevens L; Vounckx M; Dirven I; Schwarze JK; Raeymaeckers S; Forsyth R; Van Riet I; Tuyaerts S; Willard-Gallo K; Neyns B
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)
    Vounckx M; Tijtgat J; Stevens L; Dirven I; Ilsen B; Vandenbroucke F; Raeymaeckers S; Vekens K; Forsyth R; Geeraerts X; Van Riet I; Schwarze JK; Tuyaerts S; Decoster L; De Ridder M; Dufait I; Neyns B
    Cancer Immunol Immunother; 2024 Jul; 73(9):167. PubMed ID: 38954010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells.
    Tijtgat J; De Munck J; Dufait I; Schwarze JK; Van Riet I; Franceschini L; Breckpot K; Aerts JL; Neyns B; Tuyaerts S
    Front Immunol; 2021; 12():733506. PubMed ID: 34777344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic Herpes Simplex Virus Type 1 Induces Immunogenic Cell Death Resulting in Maturation of BDCA-1
    Kalus P; De Munck J; Vanbellingen S; Carreer L; Laeremans T; Broos K; Dufait I; Schwarze JK; Van Riet I; Neyns B; Breckpot K; Aerts JL
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral Immunotherapy-Update 2019.
    Hamid O; Ismail R; Puzanov I
    Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma.
    Malvehy J; Samoylenko I; Schadendorf D; Gutzmer R; Grob JJ; Sacco JJ; Gorski KS; Anderson A; Pickett CA; Liu K; Gogas H
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33785610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB-IV M1c melanoma patients.
    Fröhlich A; Niebel D; Fietz S; Egger E; Buchner A; Sirokay J; Landsberg J
    Cancer Immunol Immunother; 2020 May; 69(5):759-769. PubMed ID: 32052079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti-PD-1 therapy: MASTERKEY-115.
    Robert C; Gastman B; Gogas H; Rutkowski P; Long GV; Chaney MF; Joshi H; Lin YL; Snyder W; Chesney JA
    Eur J Cancer; 2024 Aug; 207():114120. PubMed ID: 38870745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial.
    Andtbacka RH; Ross M; Puzanov I; Milhem M; Collichio F; Delman KA; Amatruda T; Zager JS; Cranmer L; Hsueh E; Chen L; Shilkrut M; Kaufman HL
    Ann Surg Oncol; 2016 Dec; 23(13):4169-4177. PubMed ID: 27342831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
    Andtbacka RH; Kaufman HL; Collichio F; Amatruda T; Senzer N; Chesney J; Delman KA; Spitler LE; Puzanov I; Agarwala SS; Milhem M; Cranmer L; Curti B; Lewis K; Ross M; Guthrie T; Linette GP; Daniels GA; Harrington K; Middleton MR; Miller WH; Zager JS; Ye Y; Yao B; Li A; Doleman S; VanderWalde A; Gansert J; Coffin RS
    J Clin Oncol; 2015 Sep; 33(25):2780-8. PubMed ID: 26014293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma.
    Andtbacka RHI; Amatruda T; Nemunaitis J; Zager JS; Walker J; Chesney JA; Liu K; Hsu CP; Pickett CA; Mehnert JM
    EBioMedicine; 2019 Sep; 47():89-97. PubMed ID: 31409575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report.
    Fröhlich A; Hoffmann F; Niebel D; Egger E; Kukuk GM; Toma M; Sirokay J; Bieber T; Landsberg J
    Front Oncol; 2020; 10():611. PubMed ID: 32457834
    [No Abstract]   [Full Text] [Related]  

  • 15. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
    Gangi A; Zager JS
    Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma.
    Seremet T; Planken S; Schwarze JK; Jansen Y; Vandeweerd L; van den Begin R; Tsechelidis I; Lienard D; Del Marmol V; Neyns B
    Melanoma Res; 2019 Feb; 29(1):85-88. PubMed ID: 30211812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OncoVEX
    Estrada J; Zhan J; Mitchell P; Werner J; Beltran PJ; DeVoss J; Qing J; Cooke KS
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37164449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
    Harrington KJ; Puzanov I; Hecht JR; Hodi FS; Szabo Z; Murugappan S; Kaufman HL
    Expert Rev Anticancer Ther; 2015; 15(12):1389-403. PubMed ID: 26558498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions.
    Larocca CA; LeBoeuf NR; Silk AW; Kaufman HL
    Am J Clin Dermatol; 2020 Dec; 21(6):821-832. PubMed ID: 32767272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma.
    Yamazaki N; Isei T; Kiyohara Y; Koga H; Kojima T; Takenouchi T; Yokota K; Namikawa K; Yi M; Keegan A; Fukushima S
    Cancer Sci; 2022 Aug; 113(8):2798-2806. PubMed ID: 35656636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.